– Reuters Citing Source
Jefferies Downgrades Medifast to Hold, Lowers Price Target to $150
Jefferies analyst Stephanie Wissink downgrades Medifast (NYSE:MED) from Buy to Hold and lowers the price target from $345 to $150.
Related Posts
Healthcare Technology Firm Sophia Genetics Files for $100M IPO, Inks Cancer Data Deal With GE Healthcare
According to a registration statement with the SEC, Sophia Genetics SA (NASDAQ:SOPH) is looking to raise $100 million in an initial public…
Morning Brief: Top Financial Stories Dominating on Thursday, May 19
CNBC
CDC Looking Into 180 Cases Of Unexplained Pediatric Acute Hepatitis
EF Hutton Maintains Buy on Sachem Cap, Lowers Price Target to $5.5
EF Hutton analyst Edward Reilly maintains Sachem Cap (AMEX:SACH) with a Buy and lowers the price target from $7 to $5.5.